DOCSLIB.ORG

Deal Point Data Rankings Include Mergers & Acquisitions With

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Deal Point Data Rankings Include Mergers & Acquisitions With Public Mergers & Acquisitions (US & Non-US Targets) Deal Point Data rankings include mergers & acquisitions with a US or non-US public target and at least one SEC filer participant. Top Target and Acquirer M&A Financial Advisers Created: 10/Aug/2016 www.dealpointdata.com/ranking Search Criteria Target industry: Healthcare Include only highest bid in pending competing deals. Exclude withdrawn deals. Equity Value Equity Value Equity Value % Rank Rank Advice or Opinion $m $m Change Deal Count Deal Count 2016 2015 Financial Adviser 2016 2015 2015 to 2016 2016 2015 1 7 Evercore Partners 44,102 32,317 36 5 2 2 10 Guggenheim Partners 33,859 18,844 80 5 4 3 15 Bank of America Merrill Lynch 26,599 3,442 673 3 1 4 1 JPMorgan 23,628 68,999 -66 9 10 5 5 Centerview Partners LLC 13,542 42,693 -68 4 5 6 21 Rothschild Inc. 7,160 1,364 425 1 1 Skandinaviska Enskilda Banken 6 - AB 7,160 - - 1 0 8 8 Barclays 5,191 30,919 -83 2 1 9 4 Citigroup Inc. 4,767 46,899 -90 2 7 10 - Perella Weinberg Partners 1,891 - - 4 0 11 19 MTS Health Partners, L.P. 1,634 1,398 17 2 1 12 19 Credit Suisse 1,432 1,398 2 1 1 13 - RBC Capital Markets 1,285 - - 1 0 14 3 Goldman, Sachs & Co. 1,082 53,432 -98 1 9 15 2 Morgan Stanley 714 66,510 -99 1 4 16 - Duff & Phelps, LLC 391 - - 1 0 17 8 Lazard 349 30,919 -99 1 4 18 30 Roth Capital Partners, LLC 264 46 474 1 1 Stifel, Nicolaus & Company, 19 - Incorporated 141 - - 1 0 20 12 Jefferies LLC 85 6,750 -99 1 3 21 - PJT Partners 75 - - 1 0 22 - KPMG 60 - - 1 0 23 - Greenhill and Co 43 - - 1 0 24 - Oppenheimer & Co. 12 - - 1 0 Evercore Partners Alere Inc./Abbott Laboratories $4,830m American Science and Engineering, Inc./OSI Systems, Inc. $264m Envision Healthcare Holdings, Inc./AmSurg Corp. $4,905m Medivation, Inc/Sanofi SA $10,018m St. Jude Medical, Inc./Abbott Laboratories $24,085m Guggenheim Partners Alexza Pharmaceuticals, Inc./Grupo Ferrer Internacional, S.A. $17m Anacor Pharmaceuticals, Inc./Pfizer Inc. $4,503m Biotie Therapies Oyj/Acorda Therapeutics, Inc. $349m Envision Healthcare Holdings, Inc./AmSurg Corp. $4,905m St. Jude Medical, Inc./Abbott Laboratories $24,085m Bank of America Merrill Lynch LDR Holding Corporation/Zimmer Biomet Holdings, Inc. $1,082m Relypsa, Inc./Galenica AG $1,432m St. Jude Medical, Inc./Abbott Laboratories $24,085m JPMorgan Aegerion Pharmaceuticals, Inc./QLT Inc. $43m Alere Inc./Abbott Laboratories $4,830m Biotie Therapies Oyj/Acorda Therapeutics, Inc. $349m Envision Healthcare Holdings, Inc./AmSurg Corp. $4,905m HeartWare International, Inc./Medtronic Public Limited Company $1,017m iKang Healthcare Group, Inc./Yunfeng Capital $1,466m Medivation, Inc/Sanofi SA $10,018m Sagent Pharmaceuticals, Inc./Nichi-Iko Pharmaceutical Co., Ltd. $714m Sequenom, Inc./Laboratory Corporation of America Holdings $286m Centerview Partners LLC Anacor Pharmaceuticals, Inc./Pfizer Inc. $4,503m Meda AB/Mylan N.V. $7,160m Relypsa, Inc./Galenica AG $1,432m XenoPort, Inc./Arbor Pharmaceuticals, LLC $447m Rothschild Inc. Meda AB/Mylan N.V. $7,160m Skandinaviska Enskilda Banken AB Meda AB/Mylan N.V. $7,160m Barclays Envision Healthcare Holdings, Inc./AmSurg Corp. $4,905m Sequenom, Inc./Laboratory Corporation of America Holdings $286m Citigroup Inc. American Science and Engineering, Inc./OSI Systems, Inc. $264m Anacor Pharmaceuticals, Inc./Pfizer Inc. $4,503m Perella Weinberg Partners Hansen Medical, Inc./Auris Surgical Robotics Inc. $75m HeartWare International, Inc./Medtronic Public Limited Company $1,017m Nanosphere, Inc./Luminex Corporation $85m Sagent Pharmaceuticals, Inc./Nichi-Iko Pharmaceutical Co., Ltd. $714m MTS Health Partners, L.P. Biotie Therapies Oyj/Acorda Therapeutics, Inc. $349m Celator Pharmaceuticals, Inc./Jazz Pharmaceuticals plc $1,285m Credit Suisse Relypsa, Inc./Galenica AG $1,432m RBC Capital Markets Celator Pharmaceuticals, Inc./Jazz Pharmaceuticals plc $1,285m Goldman, Sachs & Co. LDR Holding Corporation/Zimmer Biomet Holdings, Inc. $1,082m Morgan Stanley Sagent Pharmaceuticals, Inc./Nichi-Iko Pharmaceutical Co., Ltd. $714m Duff & Phelps, LLC Sinovac Biotech Ltd./Investment Group $391m Sinovac Biotech Ltd./Management Led Buyout $308m Lazard Biotie Therapies Oyj/Acorda Therapeutics, Inc. $349m Roth Capital Partners, LLC American Science and Engineering, Inc./OSI Systems, Inc. $264m Stifel, Nicolaus & Company, Incorporated Symmetry Surgical Inc./RoundTable Healthcare Partners L.P. $141m Jefferies LLC Nanosphere, Inc./Luminex Corporation $85m PJT Partners Hansen Medical, Inc./Auris Surgical Robotics Inc. $75m KPMG Transition Therapeutics Inc./OPKO Health, Inc. $60m Greenhill and Co Aegerion Pharmaceuticals, Inc./QLT Inc. $43m Oppenheimer & Co. VirtualScopics, Inc./BioTelemetry, Inc. $12m.
Load more

Recommended publications
  • Investor Presentation May 2, 2018 Notices and Disclaimers
    Investor Presentation May 2, 2018 Notices and Disclaimers Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements include certain information concerning future results of operations, business strategies, financing plans, competitive position, potential growth opportunities, potential operating performance improvements, the effects of competition and the effects of future legislation or regulations. Forward-looking statements include all statements that are not historical facts and can be identified by the use of forward-looking terminology such as the words “believe,” “expect,” “plan,” “intend,” “anticipate,” “estimate,” “predict,” “potential,” “continue,” “may,” “might,” “should,” “could” or the negative of these terms or similar expressions. Forward-looking statements involve risks, uncertainties and assumptions. Actual results may differ materially from those expressed in such forward-looking statements. You should not put undue reliance on any forward-looking statements contained herein. PJT Partners undertakes no obligation to publicly update or review any forward-looking statement, whether as a result of new information, future developments or otherwise. The risk factors discussed in the “Risk Factors” section of our Annual Report on Form 10-K for the year ended December 31, 2017, filed with the United States Securities and Exchange Commission (“SEC”), as such factors may be updated from time to time in our periodic filings with the SEC, accessible on the SEC’s website at www.sec.gov, could cause the results of PJT Partners to differ materially from those expressed in forward-looking statements.
    [Show full text]
  • Employment Report
    2019 EMPLOYMENT REPORT Columbia Business School students experience unparalleled access to dynamic companies and leaders After 21 years of teaching at this institution, it is an honor to assume the role of Dean of Columbia Business School. in New York and around the world, I want to thank Dean Glenn Hubbard for his excellent joining an entrepreneurial community stewardship of the School over these last 15 years. that fosters innovation and creates Columbia Business School is ushering in a new generation of students during a critical time—one that demands we everyday impact in the global address the rapidly-evolving needs of business in the digital future. The nature of the MBA job market has changed and so too must business education, which is at an inflection point, marketplace. They build connections where data science is as important as management science. with practitioners and industry This is why we must redefine business education, by sharpening our curriculum in order to embrace how technology, data, and leaders, and tap into a lifetime algorithms are transforming business. We will need to continue to create experiential learning opportunities to better prepare students for careers in the digital future across industries. We network of more than 47,000 alumni must strengthen our engagement with the University, creating curricular opportunities for our students, and exploring spanning over 100 countries who offer collaborative research in areas of broader impact and of significant interest to the School. We must also strengthen mentoring opportunities, internships, faculty thought leadership and enhance lifelong learning by offering new courses to alumni who want to continuously and so much more.
    [Show full text]
  • Financial Rankings
    GLOBAL M&A MARKET REVIEW FINANCIAL RANKINGS 1H 2017 1H 2017 GLOBAL M&A FINANCIAL ADVISORY RANKINGS The Bloomberg M&A Advisory League Tables are the definitive publication of M&A advisory rankings. The CONTENTS tables represent the top financial and legal advisors across a broad array of deal types, regions, and industry sectors. The rankings data is comprised of mergers, acquisitions, divestitures, spin-offs, debt-for-equity- 1. Introduction swaps, joint ventures, private placements of common equity and convertible securities, and the cash 2. Global M&A Heat Map injection component of recapitalization according to Bloomberg standards. 3. Global M&A Regional Review 4. Global M&A League Tables Bloomberg M&A delivers real-time coverage of the M&A market from nine countries around the world. We 5. Americas M&A Regional Review provide a global perspective and local insight into unique deal structures in various markets through a 6. Americas M&A League Tables network of over 800 financial and legal advisory firms, ensuring an accurate reflection of key market trends. 8. EMEA M&A Regional Review Our quarterly league table rankings are a leading benchmark for legal and financial advisory performance, and our Bloomberg Brief newsletter provides summary highlights of weekly M&A activity and top deal 9. EMEA M&A League Tables trends. 12. APAC M&A Regional Review 13. APAC M&A League Tables Visit {NI LEAG CRL <GO>} to download copies of the final release and a full range of market specific league 16. Disclaimer table results. On the web, visit: http://www.bloomberg.com/professional/solutions/investment-banking/.
    [Show full text]
  • United States Court of Appeals for The
    Case 14-4353, Document 100-1, 05/16/2016, 1772362, Page1 of 37 14‐4353‐cv Apotex Inc., et al., v. Acorda Therapeutics, Inc. UNITED STATES COURT OF APPEALS FOR THE SECOND CIRCUIT August Term, 2015 (Argued: November 12, 2015 Decided: May 16, 2016) Docket No. 14‐4353‐cv ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐x APOTEX INC., et al., Plaintiffs‐Appellants, ‐ v.‐ ACORDA THERAPEUTICS, INC., Defendant‐Appellee. ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐ ‐x Before: JACOBS, LIVINGSTON and DRONEY, Circuit Judges. This appeal concerns two distinct questions: the circumstances under which the filing of a citizen petition with the Food and Drug Administration provides grounds for an antitrust claim, and the scope of false advertising Case 14-4353, Document 100-1, 05/16/2016, 1772362, Page2 of 37 liability under the Lanham Act. Plaintiffs Apotex Incorporated and Apotex Corporation appeal from the judgment of the United States District Court for the Southern District of New York (Swain, J.) that granted defendant Acorda Therapeutics, Inc.’s motion to dismiss plaintiffs’ Sherman Act claim and that granted summary judgment in favor of defendant on the Lanham Act claims (Torres, J.). Because each of these conclusions was sound, we affirm. KEITH D. PARR (with Joseph N. Froehlich, Scott B. Feder, Hugh S. Balsam, James T. Peterka, and Andy J. Miller on the brief), Locke Lord LLP, Chicago, Illinois, for Appellants Apotex Incorporated & Apotex Corporation. JOHN W. NIELDS, JR. (with Jason C. Raofield and Colin P. Watson on the brief), Covington & Burling LLP, Washington, D.C. for Appellee Acorda Therapeutics, Inc. DENNIS JACOBS, Circuit Judge: The parties are rival manufacturers of tizanidine, a drug for treating spasticity.
    [Show full text]
  • March 31, 2021
    Units Cost Market Value US Equity Index Fund US Equities 95.82% Domestic Common Stocks 10X GENOMICS INC 126 10,868 24,673 1LIFE HEALTHCARE INC 145 6,151 4,794 2U INC 101 5,298 4,209 3D SYSTEMS CORP 230 5,461 9,193 3M CO 1,076 182,991 213,726 8X8 INC 156 2,204 4,331 A O SMITH CORP 401 17,703 28,896 A10 NETWORKS INC 58 350 653 AAON INC 82 3,107 5,132 AARON'S CO INC/THE 43 636 1,376 ABBOTT LABORATORIES 3,285 156,764 380,830 ABBVIE INC 3,463 250,453 390,072 ABERCROMBIE & FITCH CO 88 2,520 4,086 ABIOMED INC 81 6,829 25,281 ABM INDUSTRIES INC 90 2,579 3,992 ACACIA RESEARCH CORP 105 1,779 710 ACADIA HEALTHCARE CO INC 158 8,583 9,915 ACADIA PHARMACEUTICALS INC 194 6,132 4,732 ACADIA REALTY TRUST 47 1,418 1,032 ACCELERATE DIAGNOSTICS INC 80 1,788 645 ACCELERON PHARMA INC 70 2,571 8,784 ACCO BRANDS CORP 187 1,685 1,614 ACCURAY INC 64 483 289 ACI WORLDWIDE INC 166 3,338 6,165 ACTIVISION BLIZZARD INC 1,394 52,457 133,043 ACUITY BRANDS INC 77 13,124 14,401 ACUSHNET HOLDINGS CORP 130 2,487 6,422 ADAPTHEALTH CORP 394 14,628 10,800 ADAPTIVE BIOTECHNOLOGIES CORP 245 11,342 10,011 ADOBE INC 891 82,407 521,805 ADT INC 117 716 1,262 ADTALEM GLOBAL EDUCATION INC 99 4,475 3,528 ADTRAN INC 102 2,202 2,106 ADVANCE AUTO PARTS INC 36 6,442 7,385 ADVANCED DRAINAGE SYSTEMS INC 116 3,153 13,522 ADVANCED ENERGY INDUSTRIES INC 64 1,704 7,213 ADVANCED MICRO DEVICES INC 2,228 43,435 209,276 ADVERUM BIOTECHNOLOGIES INC 439 8,321 1,537 AECOM 283 12,113 17,920 AERIE PHARMACEUTICALS INC 78 2,709 1,249 AERSALE CORP 2,551 30,599 31,785 AES CORP/THE 1,294 17,534 33,735 AFFILIATED
    [Show full text]
  • IN the UNITED STATES BANKRUPTCY COURT for the DISTRICT of DELAWARE ) in Re: ) Chapter 11 ) PES HOLDINGS, LLC, Et Al.,1 ) Case No
    Case 19-11626-KG Doc 130 Filed 07/31/19 Page 1 of 18 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE ) In re: ) Chapter 11 ) PES HOLDINGS, LLC, et al.,1 ) Case No. 19-11626 (KG) ) Debtors. ) (Jointly Administered) ) DEBTORS’ APPLICATION FOR ENTRY OF AN ORDER AUTHORIZING THE EMPLOYMENT AND RETENTION OF PJT PARTNERS LP AS INVESTMENT BANKER FOR THE DEBTORS AND DEBTORS IN POSSESSION, EFFECTIVE NUNC PRO TUNC TO THE PETITION DATE The above-captioned debtors and debtors in possession (collectively, the “Debtors”)2 respectfully state the following in support of this application (this “Application”). Relief Requested 1. The Debtors hereby seek entry of an order, substantially in the form attached hereto as Exhibit A (the “Order”), (a) authorizing the employment and retention of PJT Partners LP (“PJT”) as investment banker for the Debtors, in accordance with the terms and conditions set forth in that certain engagement letter, including any amendments and schedules thereto, dated as of July 12, 2019, attached to the Order as Exhibit 1 ( “Engagement Letter”), effective nunc pro tunc to the Petition Date, and (b) modifying the time keeping requirements under rule 2016(a) of 1 The Debtors in these chapter 11 cases, along with the last four digits of each Debtor’s federal tax identification number, are: PES Holdings, LLC (8157); North Yard GP, LLC (5458); North Yard Logistics, L.P. (5952); PES Administrative Services, LLC (3022); PES Energy Inc. (0661); PES Intermediate, LLC (0074); PES Ultimate Holdings, LLC (6061); and Philadelphia Energy Solutions Refining and Marketing LLC (9574). The Debtors’ service address is: 1735 Market Street, Philadelphia, Pennsylvania 19103.
    [Show full text]
  • Chapter 11 PES HOLDINGS, LLC, Et Al.,1 Case No. 18-101
    Case 18-10122-KG Doc 554 Filed 09/17/18 Page 1 of 16 IN THE UNITED STATES BANKRUPTCY COURT FOR THE DISTRICT OF DELAWARE In re: Chapter 11 PES HOLDINGS, LLC, et al.,1 Case No. 18-10122 (KG) Debtors. (Jointly Administered) SECOND INTERIM AND FINAL FEE APPLICATION OF PJT PARTNERS LP AS INVESTMENT BANKER TO THE DEBTORS FOR ALLOWANCE (AND FINAL APPROVAL) OF COMPENSATION FOR SERVICES RENDERED AND FOR THE REIMBURSEMENT OF ALL ACTUAL AND NECESSARY OUT-OF-POCKET EXPENSES INCURRED FOR THE PERIOD OF JANUARY 21, 2018 THROUGH APRIL 2, 2018 Name of Applicant: PJT Partners LP Authorized to Provide Professional Services to: Debtors Date of Retention: Order entered on February 23, 2018 approving the retention of PJT Partners LP nunc pro tunc to January 21, 2018 [Docket No. 195] Period for which Compensation and Expense Reimbursement is sought: January 21, 2018 through April 2, 2018 Amount of Compensation sought as actual, reasonable and necessary: $2,798,763.44 Amount of Expense Reimbursement requested as actual, reasonable and necessary: $11,640.00 Payment Sought: $0.00 This is an: __ monthly x interim x final application 1 The Debtors in these chapter 11 cases, along with the last four digits of each Debtor's federal tax identification number, are: PES Holdings, LLC (8157); North Yard Financing, LLC (6284); North Yard GP, LLC (5458); North Yard Logistics, L.P. (952): PES Administrative Services_ LL,C (3022); PES Logistics GP, LLC (9202); PES Logistics Partners, L.P. (1288); PESRM Holdings, LLC (2107), aid Philadelphia Energy Solutions Refining and Marketing LLC (974).
    [Show full text]
  • Companies in Attendance
    COMPANIES IN ATTENDANCE Abbott Diabetes Care Archbow Consulting LLC Business One Technologies Abbott Laboratories ARKRAY USA BusinessOneTech AbbVie Armory Hill Advocates, LLC CastiaRX ACADIA Artia Solutions Catalyst Acaria Health Asembia Celgene Accredo Assertio Therapeutics Celltrion Acer Therapeutics AssistRx Center for Creative Leadership Acorda Therapeutics Astellas Pharma US Inc. Cigna Actelion AstraZeneca Cigna Specialty Pharmacy AdhereTech Athenex Oncology Circassia Advantage Point Solutions Avanir Coeus Consulting Group Aerie Pharmaceuticals Avella Coherus Biosciences AGIOS AveXis Collaborative Associates LLC Aimmune Theraputics Bank of America Collegium Akcea Therapeutics Bausch Health Corsica Life Sciences Akebia Therapeutics Bayer U.S. CoverMyMeds Alder BioPharmaceuticals Becton Dickinson Creehan & Company, Inc., an Inovalon Company Alexion Biofrontera CSL Behring Alkermes Biogen Curant Health Allergan Biohaven CVS Health Almirall BioMarin D2 Consulting Alnylam BioMatrix Specialty Pharmacy Daiichi Sankyo Amarin BioPlus Specialty Pharmacy DBV Technologies Amber Pharmacy Bioventus Deloitte Consulting LLP AmerisourceBergen Blue Cross Blue Shield Association Dendreon Amgen Blue Fin Group Dermira Amicus Therapeutics bluebird bio Dexcom Amneal Boehringer Ingelheim Diplomat Pharmacy Anthem Boston Biomedical Dova Applied Policy Bowler and Company Decision Resources Group Aquestive Therapeutics Braeburn Eisai Arbor Pharmaceuticals Bristol-Myers Squibb 1 electroCore Indivior Merz Pharmaceuticals EMD Serono Inside Rx Milliman Encore Dermatology,
    [Show full text]
  • 18Th Annual M&A Advisor Awards Finalists I. Sector
    18TH ANNUAL M&A ADVISOR AWARDS FINALISTS I. SECTOR DEAL OF THE YEAR ENERGY DEAL OF THE YEAR Acquisition of Oildex by DrillingInfo Vaquero Capital Intertek Restructuring of PetroQuest Energy FTI Consulting Heller, Draper, Patrick, Horn & Manthey, LLC. Houlihan Lokey Akin Gump Seaport Global Securities Porter Hedges LLP Dacarba Subordinated Preferred Equity Investment into Energy Distribution Partners Jordan, Knauff & Company Energy Distribution Partners Acquisition of Westinghouse Electric Company by Brookfield Business Partners Pillsbury Winthrop Shaw Pittman LLP Milbank, Tweed, Hadley & McCloy LLP Weil, Gotshal & Manges Willkie Farr & Gallagher LLP Recapitalization of kV Power by Rock Hill Capital Romanchuk & Co. Rock Hill Capital Atkins, Hollmann, Jones, Peacock, Lewis & Lyon, Inc. Restructuring of Jones Energy, Inc. Epiq Jackson Walker L.L.P Kirkland & Ellis Davis Polk & Wardwell LLP Merger of Transocean and Ocean Rig Seward & Kissel LLP King & Spalding LLP Transocean Ltd. Hamburger Ocean Rig UDW Inc. Maples and Calder Ogier Wenger & Vieli Ltd Acquisition of EQT Core Conventional Appalachia by Diversified Gas & Oil PLC Stifel RBC FINANCIALS DEAL OF THE YEAR Acquisition of First Team Resources Corporation by King Bancshares, Inc. GLC Advisors & Co. K Coe Isom Morris Laing King Bancshares, Inc. First Team Resources Corporation Stinson Merger of LourdMurray with Delphi Private Advisors, with an investment from HighTower Republic Capital Group HighTower LourdMurray Solomon Ward Seidenwurm & Smith, LLP Delphii Private Advisors 1 Acquisition of 1st Global Inc. by Blucora Inc. Haynes and Boone, LLP PJT Partners Foley & Lardner, LLP Blucora ERG Capital Merger of National Commerce Corporation with and into CenterState Bank Corporation Maynard Cooper & Gale P.C. Raymond James Nelson Mullins Riley & Scarbrough Keefe, Bruyette & Woods Inc.
    [Show full text]
  • Including League Tables of Financial Advisors
    An Acuris Company Finding the opportunities in mergers and acquisitions Global & Regional M&A Report 2019 Including League Tables of Financial Advisors mergermarket.com An Acuris Company Content Overview 03 Global 04 Global Private Equity 09 Europe 14 US 19 Latin America 24 Asia Pacific (excl. Japan) 29 Japan 34 Middle East & Africa 39 M&A and PE League Tables 44 Criteria & Contacts 81 mergermarket.com Mergermarket Global & Regional Global Overview 3 M&A Report 2019 Global Overview Regional M&A Comparison North America USD 1.69tn 1.5% vs. 2018 Inbound USD 295.8bn 24.4% Outbound USD 335.3bn -2.9% PMB USD 264.4bn 2.2x Latin America USD 85.9bn 12.5% vs. 2018 Inbound USD 56.9bn 61.5% Outbound USD 8.9bn 46.9% EMU USD 30.6bn 37.4% 23.1% Europe USD 770.5bn -21.9% vs. 2018 50.8% 2.3% Inbound USD 316.5bn -30.3% Outbound USD 272.1bn 28.3% PMB USD 163.6bn 8.9% MEA USD 141.2bn 102% vs. 2018 Inbound USD 49.2bn 29% Outbound USD 22.3bn -15.3% Ind. & Chem. USD 72.5bn 5.2x 4.2% 17% 2.6% APAC (ex. Japan) USD 565.3bn -22.5% vs. 2018 Inbound USD 105.7bn -14.8% Outbound USD 98.9bn -24.5% Ind. & Chem. USD 111.9bn -5.3% Japan USD 75.4bn 59.5% vs. 2018 Inbound USD 12.4bn 88.7% Global M&A USD 3.33tn -6.9% vs. 2018 Outbound USD 98.8bn -43.6% Technology USD 21.5bn 2.8x Cross-border USD 1.27tn -6.2% vs.
    [Show full text]
  • Equity Research 388 Companies Under Coverage
    Equity Research 388 Companies Under Coverage Financial Services Commercial Finance Consumer Finance & Financial Technology Insurance Investment Banks, Brokers & Alternative Asset Managers Devin Ryan David Scharf Matthew Carletti Devin Ryan (212) 906-3578 (415) 835-8942 (312) 768-1784 (212) 906-3578 Ares Capital Corp. (ARCC) Alliance Data Systems Corp. (ADS) Alleghany Corp. (Y) James River Group Holdings (JRVR) Apollo Global Management (APO) BlackRock TCP Capital Corp. (TCPC) Credit Acceptance Corp. (CACC) The Allstate Corp. (ALL) Kemper Corp. (KMPR) The Blackstone Group (BX) Capital Southwest Corp. (CSWC) Elevate Credit (ELVT) AMERISAFE (AMSF) Kinsale Capital Group (KNSL) The Charles Schwab Corp. (SCHW) Hercules Capital (HTGC) Encore Capital Group (ECPG) Arch Capital Group (ACGL) Lemonade (LMND) Cowen Group (COWN) Oaktree Specialty Lending Corp. (OCSL) Enova International (ENVA) Argo Group International Holdings (ARGO) Midwest Holding (MDWT) Envestnet (ENV) Owl Rock Capital Corp. (ORCC) FirstCash (FCFS) AXIS Capital Holdings (AXS) Old Republic International Corp. (ORI) Evercore (EVR) PennantPark Floating Rate Capital (PFLT) International Money Express (IMXI) Chubb (CB) Palomar Holdings (PLMR) Fortress Transportation and Infrastructure Investors (FTAI) PennantPark Investment Corp. (PNNT) MoneyGram International (MGI) Doma Holdings (DOMA) ProAssurance Corp. (PRA) The Goldman Sachs Group (GS) Sixth Street Specialty Lending (TSLX) OneMain Holdings (OMF) Employers Holdings (EIG) RenaissanceRe Holdings (RNR) Greenhill & Co. (GHL) SuRo Capital
    [Show full text]
  • Global Equity Fund Description Plan 3S DCP & JRA MICROSOFT CORP
    Global Equity Fund June 30, 2020 Note: Numbers may not always add up due to rounding. % Invested For Each Plan Description Plan 3s DCP & JRA MICROSOFT CORP 2.5289% 2.5289% APPLE INC 2.4756% 2.4756% AMAZON COM INC 1.9411% 1.9411% FACEBOOK CLASS A INC 0.9048% 0.9048% ALPHABET INC CLASS A 0.7033% 0.7033% ALPHABET INC CLASS C 0.6978% 0.6978% ALIBABA GROUP HOLDING ADR REPRESEN 0.6724% 0.6724% JOHNSON & JOHNSON 0.6151% 0.6151% TENCENT HOLDINGS LTD 0.6124% 0.6124% BERKSHIRE HATHAWAY INC CLASS B 0.5765% 0.5765% NESTLE SA 0.5428% 0.5428% VISA INC CLASS A 0.5408% 0.5408% PROCTER & GAMBLE 0.4838% 0.4838% JPMORGAN CHASE & CO 0.4730% 0.4730% UNITEDHEALTH GROUP INC 0.4619% 0.4619% ISHARES RUSSELL 3000 ETF 0.4525% 0.4525% HOME DEPOT INC 0.4463% 0.4463% TAIWAN SEMICONDUCTOR MANUFACTURING 0.4337% 0.4337% MASTERCARD INC CLASS A 0.4325% 0.4325% INTEL CORPORATION CORP 0.4207% 0.4207% SHORT-TERM INVESTMENT FUND 0.4158% 0.4158% ROCHE HOLDING PAR AG 0.4017% 0.4017% VERIZON COMMUNICATIONS INC 0.3792% 0.3792% NVIDIA CORP 0.3721% 0.3721% AT&T INC 0.3583% 0.3583% SAMSUNG ELECTRONICS LTD 0.3483% 0.3483% ADOBE INC 0.3473% 0.3473% PAYPAL HOLDINGS INC 0.3395% 0.3395% WALT DISNEY 0.3342% 0.3342% CISCO SYSTEMS INC 0.3283% 0.3283% MERCK & CO INC 0.3242% 0.3242% NETFLIX INC 0.3213% 0.3213% EXXON MOBIL CORP 0.3138% 0.3138% NOVARTIS AG 0.3084% 0.3084% BANK OF AMERICA CORP 0.3046% 0.3046% PEPSICO INC 0.3036% 0.3036% PFIZER INC 0.3020% 0.3020% COMCAST CORP CLASS A 0.2929% 0.2929% COCA-COLA 0.2872% 0.2872% ABBVIE INC 0.2870% 0.2870% CHEVRON CORP 0.2767% 0.2767% WALMART INC 0.2767%
    [Show full text]